Anthera Pharmaceuticals Inc 4
4 · Anthera Pharmaceuticals Inc · Filed May 22, 2017
Insider Transaction Report
Form 4
Dickinson Klara
SVP & Chief Regulatory Officer
Transactions
- Award
Stock option (right to buy)
2017-05-20+43,750→ 43,750 totalExercise: $1.63Exp: 2027-05-20→ Common Stock (43,750 underlying)
Footnotes (1)
- [F1]This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027.